Clinical Trial Update: A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and treatment effect of abicipar pegol for neovascular age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Abicipar Pegol (Abicipar Pegol)

Snippet

Sponsor: Allergan | Conditions: Macular Degeneration | Phase 2 | Status: COMPLETED | Results posted: 2020-08-03